Clinical trial • Phase I • Endocrinology
NNC0497-0040 for Type 1 diabetes|Overweight|Obesity
Phase I trial of NNC0497-0040 for Type 1 diabetes|Overweight|Obesity. 146 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Type 1 diabetes|Overweight|Obesity
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 26-02-2026
- First CTIS Authorization Date
- 23-04-2026
Trial design
Phase I trial across 1 site in Germany.
- Target Sample Size
- 146
Eligibility
Recruits 146 Vulnerable population not selected; no vulnerable population considerations described..
- Vulnerable Population
- Vulnerable population not selected; no vulnerable population considerations described.
Recruitment
- Planned Sample Size
- 146
- Recruitment Window Months
- 20
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 146
Germany
- Earliest CTIS Part Ii Submission Date
- 14-04-2026
- Latest Decision Or Authorization Date
- 23-04-2026
- Processing Time Days
- 9
- Number Of Sites
- 1
- Number Of Participants
- 146
Sites
- Site Name
- PROFIL Institut fuer Stoffwechselforschung GmbH
- Contact Person Name
- Grit Andersen
- Contact Person Email
- grit.andersen@profil.com
Sponsor
Primary sponsor
- Full Name
- Novo Nordisk A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- NNC0497-0040
Related trials
Other published trials that may interest you.